Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA)’s stock price has decreased by -1.91 compared to its previous closing price of 16.75. However, the company has seen a -3.97% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-08 that TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024. The presentation will begin at 8:30 A.M. Greenwich Mean Time (3.30 A.M. Eastern Time).
Is It Worth Investing in Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Right Now?
The 36-month beta value for TEVA is at 0.81. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 4 rating it as “overweight,” 17 as “hold,” and 5 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TEVA is 1.13B, and currently, shorts hold a 1.60% of that float. The average trading volume for TEVA on November 18, 2024 was 6.52M shares.
TEVA’s Market Performance
The stock of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has seen a -3.97% decrease in the past week, with a -8.52% drop in the past month, and a -10.17% fall in the past quarter. The volatility ratio for the week is 2.27%, and the volatility levels for the past 30 days are at 2.67% for TEVA. The simple moving average for the past 20 days is -8.07% for TEVA’s stock, with a 2.34% simple moving average for the past 200 days.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with Argus repeating the rating for TEVA by listing it as a “Buy.” The predicted price for TEVA in the upcoming period, according to Argus is $20 based on the research report published on July 10, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $14. The rating they have provided for TEVA stocks is “Neutral” according to the report published on March 08th, 2024.
Piper Sandler gave a rating of “Overweight” to TEVA, setting the target price at $19 in the report published on February 12th of the current year.
TEVA Trading at -7.58% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.91% of loss for the given period.
Volatility was left at 2.67%, however, over the last 30 days, the volatility rate increased by 2.27%, as shares sank -8.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.13% lower at present.
During the last 5 trading sessions, TEVA fell by -3.97%, which changed the moving average for the period of 200-days by +31.86% in comparison to the 20-day moving average, which settled at $17.87. In addition, Teva- Pharmaceutical Industries Ltd. ADR saw 57.38% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Daniell Richard, who sale 98,943 shares at the price of $17.30 back on Aug 12 ’24. After this action, Daniell Richard now owns 0 shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $1,711,447 using the latest closing price.
Grant Angus, the EVP, Business Development of Teva- Pharmaceutical Industries Ltd. ADR, sale 4,065 shares at $17.28 during a trade that took place back on Aug 09 ’24, which means that Grant Angus is holding 8,848 shares at $70,243 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.5 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.06. The total capital return value is set at 0.08. Equity return is now at value -14.76, with -2.29 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at 0.13. The debt to equity ratio resting at 3.13. The interest coverage ratio of the stock is 2.18.
Currently, EBITDA for the company is 4.33 billion with net debt to EBITDA at 7.88. When we switch over and look at the enterprise to sales, we see a ratio of 2.06. The receivables turnover for the company is 4.85for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.
Conclusion
In conclusion, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
